, a developer of embryonic stem-cell therapies, rose after the company reported quarterly earnings and revenue that exceeded expectations.
For the third quarter of 2006, the company reported a loss of $9.8 million, or 15 cents a share, compared with a loss of $11.9 million, or 21 cents a share, a year ago. Analysts were expecting a loss of 16 cents a share.
Geron's revenue, which comes from royalty and license fees with oncology, diagnostics, research and agriculture companies, reached $723,000, up from $673,000 last year. Analysts were looking for $690,000, according to Thomson First Call.
Shares were up 3.1% to $8.09.